Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spinal Concepts Warned Over QSR Violations, Unverified Design Changes

This article was originally published in The Gray Sheet

Executive Summary

Abbott is in the process of integrating wholly-owned subsidiary Spinal Concepts into its quality systems program in order to assure a more systematic approach and greater level of compliance with FDA, according to company reps

You may also be interested in...

J&J/DePuy Charité To Be First Artificial Spinal Disc Reviewed By FDA Panel

FDA's Orthopaedic & Rehabilitation Devices Panel will meet June 2 to review a PMA for Johnson & Johnson/DePuy's Charité artificial lumbar disc for degenerative disc disease

Abbott’s Lake County Plant Gets FDA Nod; Prism Squares Up For U.S. Debut

Abbott Labs will begin U.S. commercialization of its Prism, Architect and AxSYM full diagnostic assay menus over the next 12 months, following FDA's decision to end a four-year prohibition of product sales

Abbott Picks Spinal Concepts As Market Entry; InFix Device Approval Awaited

Abbott Labs' entry into the orthopedics market through the $170 mil. purchase of Spinal Concepts mirrors its cardiovascular devices business strategy, according to the firm




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts